Structure-based development of PDEδ inhibitors

Biol Chem. 2017 May 1;398(5-6):535-545. doi: 10.1515/hsz-2016-0272.

Abstract

The prenyl binding protein PDEδ enhances the diffusion of farnesylated Ras proteins in the cytosol, ultimately affecting their correct localization and signaling. This has turned PDEδ into a promising target to prevent oncogenic KRas signaling. In this review we summarize and describe the structure-guided-development of the three different PDEδ inhibitor chemotypes that have been documented so far. We also compare both their potency for binding to the PDEδ pocket and their in vivo efficiency in suppressing oncogenic KRas signaling, as a result of the inhibition of the PDEδ/KRas interaction.

Keywords: KRas; PDEδ; small molecules; structure-based design; structure-property-relationships.

Publication types

  • Review

MeSH terms

  • Animals
  • Benzimidazoles / chemistry
  • Benzimidazoles / pharmacology
  • Cyclic Nucleotide Phosphodiesterases, Type 6 / antagonists & inhibitors*
  • Drug Discovery / methods*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Pyridazines / chemistry
  • Pyridazines / pharmacology

Substances

  • Benzimidazoles
  • Enzyme Inhibitors
  • Pyridazines
  • pyridazine
  • benzimidazole
  • Cyclic Nucleotide Phosphodiesterases, Type 6